Drug intelligence / Profile preview

MPS-106

Development stage: Unknown
Lead developer: Fondazione Ricerca Traslazionale
Modality: Small Molecules
Administration: Oral

Overview

MPS-106 is an orally bioavailable small-molecule inhibitor of the c-MET (Hepatocyte Growth Factor Receptor) tyrosine kinase. Developed by the Fondazione Ricerca Traslazionale (FoRT), it is designed to target the HGF/MET signaling pathway, which plays a critical role in tumor cell proliferation, survival, and metastasis. MPS-106 is primarily being evaluated for the treatment of advanced non-small cell lung cancer (NSCLC), specifically in patients with MET alterations such as MET exon 14 skipping mutations or MET gene amplification. It is also being explored as a strategy to overcome resistance to EGFR tyrosine kinase inhibitors in NSCLC.

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on MPS-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MPS-106.

Explore the full profile